1
|
Singh P, Beyl RA, Stephens JM, Noland RC, Richard AJ, Boudreau A, Hebert RC, Ravussin E, Broussard JL, St-Onge MP, Marlatt KL. Effect of sleep restriction on insulin sensitivity and energy metabolism in postmenopausal women: A randomized crossover trial. Obesity (Silver Spring) 2023; 31:1204-1215. [PMID: 36998155 DOI: 10.1002/oby.23739] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 01/10/2023] [Accepted: 01/26/2023] [Indexed: 04/01/2023]
Abstract
OBJECTIVE The aim of this study was to investigate the effect of sleep restriction (SR) on insulin sensitivity and energy metabolism in postmenopausal women. METHODS In a randomized crossover trial, 14 women underwent four nights of habitual sleep (HS, 100% normal sleep) and SR (60% of HS) while following a eucaloric diet. Outcomes included the following: (1) insulin sensitivity by hyperinsulinemic-euglycemic clamp, defined as the glucose infusion rate (GIR); (2) resting metabolism and substrate oxidation by indirect calorimetry; and (3) glucose, insulin, and C-peptide concentrations following a standard meal test. RESULTS Nine postmenopausal women (mean [SD], age 59 [4] years, BMI 28.0 [2.6] kg/m2 ) were analyzed. Accelerometer-determined total time in bed was 8.4 ± 0.6 hours during HS versus 5.0 ± 0.4 hours during SR (38% reduction, p < 0.0001). SR reduced low-dose insulin GIR by 20% (HS: 2.55 ± 0.22 vs. SR: 2.03 ± 0.20 mg/kg/min; p = 0.01) and high-dose insulin GIR by 12% (HS: 10.48 ± 0.72 vs. SR: 9.19 ± 0.72 mg/kg/min; p < 0.001). SR reduced fat oxidation during high-dose insulin infusion (p < 0.01), and it did not alter resting energy metabolism. CONCLUSIONS Four nights of SR reduced insulin sensitivity and fat oxidation in postmenopausal women. These findings underscore the role of insufficient sleep in metabolic dysfunction following menopause. Larger trials investigating how sleep disturbances cause metabolic dysfunction during menopause are needed across all stages of menopause.
Collapse
Affiliation(s)
- Prachi Singh
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - Robbie A Beyl
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | | | - Robert C Noland
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | | | - Anik Boudreau
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - R Caitlin Hebert
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - Eric Ravussin
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - Josiane L Broussard
- Department of Health & Exercise Science, Colorado State University, Fort Collins, Colorado, USA
| | - Marie-Pierre St-Onge
- Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Kara L Marlatt
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| |
Collapse
|
2
|
Ribnicky D, Kim SB, Poulev A, Wang Y, Boudreau A, Raskin I, Bisson J, Ray GJ, Chen SN, Richard A, Stephens JM, Pauli GF. Prenylated Coumaric Acids from Artemisia scoparia Beneficially Modulate Adipogenesis. J Nat Prod 2021; 84:1078-1086. [PMID: 33830759 PMCID: PMC8132292 DOI: 10.1021/acs.jnatprod.0c01149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Two new diprenylated coumaric acid isomers (1a and 1b) and two known congeners, capillartemisin A (2) and B (3), were isolated from Artemisia scoparia as bioactive markers using bioactivity-guided HPLC fractionation. Their structures were determined by spectroscopic means, including 1D and 2D NMR methods and LC-MS, with their purity assessed by 1D 1H pure shift qNMR spectroscopic analysis. The bioactivity of compounds was evaluated by enhanced accumulation of lipids, as measured using Oil Red O staining, and by increased expression of several adipocyte marker genes, including adiponectin in 3T3-L1 adipocytes relative to untreated negative controls. Compared to the plant's 80% EtOH extract, these purified compounds showed significant but still weaker inhibition of TNFα-induced lipolysis in 3T3-L1 adipocytes. This suggests that additional bioactive substances are responsible for the multiple metabolically favorable effects on adipocytes observed with Artemisia scoparia extract.
Collapse
Affiliation(s)
- David Ribnicky
- Corresponding Authors Tel: +1 312 355 1949 Fax: +1 312 413 5894 (David Ribnicky): (Guido Pauli):
| | - Seon Beom Kim
- Corresponding Authors Tel: +1 312 355 1949 Fax: +1 312 413 5894 (David Ribnicky): (Guido Pauli):
| | - Alexander Poulev
- Department of Plant Biology, Rutgers University, New Brunswick, New Jersey 08901, United States
| | - Yang Wang
- Department of Plant Biology, Rutgers University, New Brunswick, New Jersey 08901, United States
| | - Anik Boudreau
- Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808, United States
| | - Ilya Raskin
- Department of Plant Biology, Rutgers University, New Brunswick, New Jersey 08901, United States
| | - Jonathan Bisson
- Center for Natural Product Technologies, Pharmacognosy Institute, and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Illinois 60612, United States
| | - G. Joseph Ray
- Pharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Illinois 60612, United States
| | - Shao-Nong Chen
- Center for Natural Product Technologies, Pharmacognosy Institute, and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Illinois 60612, United States
| | - Allison Richard
- Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808, United States
| | - Jacqueline M. Stephens
- Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808, United States
| | - Guido F. Pauli
- Corresponding Authors Tel: +1 312 355 1949 Fax: +1 312 413 5894 (David Ribnicky): (Guido Pauli):
| |
Collapse
|
3
|
Boudreau A, Richard AJ, Harvey I, Stephens JM. Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use. Front Endocrinol (Lausanne) 2021; 12:727061. [PMID: 35211087 PMCID: PMC8861327 DOI: 10.3389/fendo.2021.727061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 12/16/2021] [Indexed: 11/19/2022] Open
Abstract
Botanicals have a long history of medicinal use for a multitude of ailments, and many modern pharmaceuticals were originally isolated from plants or derived from phytochemicals. Among these, artemisinin, first isolated from Artemisia annua, is the foundation for standard anti-malarial therapies. Plants of the genus Artemisia are among the most common herbal remedies across Asia and Central Europe. The species Artemisia scoparia (SCOPA) is widely used in traditional folk medicine for various liver diseases and inflammatory conditions, as well as for infections, fever, pain, cancer, and diabetes. Modern in vivo and in vitro studies have now investigated SCOPA's effects on these pathologies and its ability to mitigate hepatotoxicity, oxidative stress, obesity, diabetes, and other disease states. This review focuses on the effects of SCOPA that are particularly relevant to metabolic health. Indeed, in recent years, an ethanolic extract of SCOPA has been shown to enhance differentiation of cultured adipocytes and to share some properties of thiazolidinediones (TZDs), a class of insulin-sensitizing agonists of the adipogenic transcription factor PPARγ. In a mouse model of diet-induced obesity, SCOPA diet supplementation lowered fasting insulin and glucose levels, while inducing metabolically favorable changes in adipose tissue and liver. These observations are consistent with many lines of evidence from various tissues and cell types known to contribute to metabolic homeostasis, including immune cells, hepatocytes, and pancreatic beta-cells. Compounds belonging to several classes of phytochemicals have been implicated in these effects, and we provide an overview of these bioactives. The ongoing global epidemics of obesity and metabolic disease clearly require novel therapeutic approaches. While the mechanisms involved in SCOPA's effects on metabolic, anti-inflammatory, and oxidative stress pathways are not fully characterized, current data support further investigation of this plant and its bioactives as potential therapeutic agents in obesity-related metabolic dysfunction and many other conditions.
Collapse
Affiliation(s)
- Anik Boudreau
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, United States
| | - Allison J. Richard
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, United States
| | - Innocence Harvey
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, United States
| | - Jacqueline M. Stephens
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, United States
- Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, United States
- *Correspondence: Jacqueline M. Stephens,
| |
Collapse
|
4
|
Abstract
Adipose, or fat, tissue (AT) was once considered an inert tissue that primarily existed to store lipids, and was not historically recognized as an important organ in the regulation and maintenance of health. With the rise of obesity and more rigorous research, AT is now recognized as a highly complex metabolic organ involved in a host of important physiological functions, including glucose homeostasis and a multitude of endocrine capabilities. AT dysfunction has been implicated in several disease states, most notably obesity, metabolic syndrome and type 2 diabetes. The study of AT has provided useful insight in developing strategies to combat these highly prevalent metabolic diseases. This review highlights the major functions of adipose tissue and the consequences that can occur when disruption of these functions leads to systemic metabolic dysfunction.
Collapse
Affiliation(s)
- Innocence Harvey
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
| | - Anik Boudreau
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
| | - Jacqueline M Stephens
- Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.,Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA
| |
Collapse
|
5
|
Boudreau A, Burke S, Collier J, Richard AJ, Ribnicky DM, Stephens JM. Mechanisms of Artemisia scoparia's Anti-Inflammatory Activity in Cultured Adipocytes, Macrophages, and Pancreatic β-Cells. Obesity (Silver Spring) 2020; 28:1726-1735. [PMID: 32741148 PMCID: PMC7483878 DOI: 10.1002/oby.22912] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 04/22/2020] [Accepted: 05/11/2020] [Indexed: 12/19/2022]
Abstract
OBJECTIVE An ethanolic extract of Artemisia scoparia (SCO) improves adipose tissue function and reduces negative metabolic consequences of high-fat feeding. A. scoparia has a long history of medicinal use across Asia and has anti-inflammatory effects in various cell types and disease models. The objective of the current study was to investigate SCO's effects on inflammation in cells relevant to metabolic health. METHODS Inflammatory responses were assayed in cultured adipocytes, macrophages, and insulinoma cells by quantitative polymerase chain reaction, immunoblotting, and NF-κB reporter assays. RESULTS In tumor necrosis factor α-treated adipocytes, SCO mitigated ERK and NF-κB signaling as well as transcriptional responses but had no effect on fatty acid-binding protein 4 secretion. SCO also reduced levels of deleted in breast cancer 1 protein in adipocytes and inhibited inflammatory gene expression in stimulated macrophages. Finally, in pancreatic β-cells, SCO decreased NF-κB-responsive promoter activity induced by IL-1β treatment. CONCLUSIONS SCO's ability to promote adipocyte development and function is thought to mediate its insulin-sensitizing actions in vivo. Our findings that SCO inhibits inflammatory responses through at least two distinct signaling pathways (ERK and NF-κB) in three cell types known to contribute to metabolic disease reveal that SCO may act more broadly than previously thought to improve metabolic health.
Collapse
Affiliation(s)
- Anik Boudreau
- Pennington Biomedical Research Center, Baton Rouge, LA 70808
| | - Susan Burke
- Pennington Biomedical Research Center, Baton Rouge, LA 70808
| | - Jason Collier
- Pennington Biomedical Research Center, Baton Rouge, LA 70808
| | | | - David M. Ribnicky
- Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ
| | - Jacqueline M. Stephens
- Pennington Biomedical Research Center, Baton Rouge, LA 70808
- Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803
- To whom correspondence should be addressed: Jacqueline Stephens, Louisiana State University, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, Phone (225) 763-2648, FAX (225) 578-2597,
| |
Collapse
|
6
|
Boudreau A, Poulev A, Ribnicky DM, Raskin I, Rathinasabapathy T, Richard AJ, Stephens JM. Distinct Fractions of an Artemisia scoparia Extract Contain Compounds With Novel Adipogenic Bioactivity. Front Nutr 2019; 6:18. [PMID: 30906741 PMCID: PMC6418310 DOI: 10.3389/fnut.2019.00018] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 02/11/2019] [Indexed: 12/19/2022] Open
Abstract
Adipocytes are important players in metabolic health and disease, and disruption of adipocyte development or function contributes to metabolic dysregulation. Hence, adipocytes are significant targets for therapeutic intervention in obesity and metabolic syndrome. Plants have long been sources for bioactive compounds and drugs. In previous studies, we screened botanical extracts for effects on adipogenesis in vitro and discovered that an ethanolic extract of Artemisia scoparia (SCO) could promote adipocyte differentiation. To follow up on these studies, we have used various separation methods to identify the compound(s) responsible for SCO's adipogenic properties. Fractions and subfractions of SCO were tested for effects on lipid accumulation and adipogenic gene expression in differentiating 3T3-L1 adipocytes. Fractions were also analyzed by Ultra Performance Liquid Chromatography- Mass Spectrometry (UPLC-MS), and resulting peaks were putatively identified through high resolution, high mass accuracy mass spectrometry, literature data, and available natural products databases. The inactive fractions contained mostly quercetin derivatives and chlorogenates, including chlorogenic acid and 3,5-dicaffeoylquinic acid, which had no effects on adipogenesis when tested individually, thus ruling them out as pro-adipogenic bioactives in SCO. Based on these studies we have putatively identified the principal constituents in SCO fractions and subfractions that promoted adipocyte development and fat cell gene expression as prenylated coumaric acids, coumarin monoterpene ethers, 6-demethoxycapillarisin and two polymethoxyflavones.
Collapse
Affiliation(s)
- Anik Boudreau
- Pennington Biomedical Research Center, Baton Rouge, LA, United States
| | - Alexander Poulev
- Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ, United States
| | - David M Ribnicky
- Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ, United States
| | - Ilya Raskin
- Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ, United States
| | | | - Allison J Richard
- Pennington Biomedical Research Center, Baton Rouge, LA, United States
| | - Jacqueline M Stephens
- Pennington Biomedical Research Center, Baton Rouge, LA, United States.,Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, United States
| |
Collapse
|
7
|
Boudreau A, Richard AJ, Burrell JA, King WT, Dunn R, Schwarz JM, Ribnicky DM, Rood J, Salbaum JM, Stephens JM. An ethanolic extract of Artemisia scoparia inhibits lipolysis in vivo and has antilipolytic effects on murine adipocytes in vitro. Am J Physiol Endocrinol Metab 2018; 315:E1053-E1061. [PMID: 30153067 PMCID: PMC6293162 DOI: 10.1152/ajpendo.00177.2018] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
An ethanolic extract of Artemisia scoparia (SCO) has metabolically favorable effects on adipocyte development and function in vitro and in vivo. In diet-induced obese mice, SCO supplementation significantly reduced fasting glucose and insulin levels. Given the importance of adipocyte lipolysis in metabolic health, we hypothesized that SCO modulates lipolysis in vitro and in vivo. Free fatty acids and glycerol were measured in the sera of mice fed a high-fat diet with or without SCO supplementation. In cultured 3T3-L1 adipocytes, the effects of SCO on lipolysis were assessed by measuring glycerol and free fatty acid release. Microarray analysis, qPCR, and immunoblotting were used to assess gene expression and protein abundance. We found that SCO supplementation of a high-fat diet in mice substantially reduces circulating glycerol and free fatty acid levels, and we observed a cell-autonomous effect of SCO to significantly attenuate tumor necrosis factor-α (TNFα)-induced lipolysis in cultured adipocytes. Although several prolipolytic and antilipolytic genes were identified by microarray analysis of subcutaneous and visceral adipose tissue from SCO-fed mice, regulation of these genes did not consistently correlate with SCO's ability to reduce lipolytic metabolites in sera or cell culture media. However, in the presence of TNFα in cultured adipocytes, SCO induced antilipolytic changes in phosphorylation of hormone-sensitive lipase and perilipin. Together, these data suggest that the antilipolytic effects of SCO on adipose tissue play a role in the ability of this botanical extract to improve whole body metabolic parameters and support its use as a dietary supplement to promote metabolic resiliency.
Collapse
Affiliation(s)
- Anik Boudreau
- Pennington Biomedical Research Center, Louisiana State University , Baton Rouge, Louisiana
| | - Allison J Richard
- Pennington Biomedical Research Center, Louisiana State University , Baton Rouge, Louisiana
| | - Jasmine A Burrell
- Department of Biological Sciences, Louisiana State University , Baton Rouge, Louisiana
| | - William T King
- Department of Biological Sciences, Louisiana State University , Baton Rouge, Louisiana
| | - Ruth Dunn
- Department of Biological Sciences, Louisiana State University , Baton Rouge, Louisiana
| | | | - David M Ribnicky
- Department of Plant Biology and Pathology, Rutgers University , New Brunswick, New Jersey
| | - Jennifer Rood
- Pennington Biomedical Research Center, Louisiana State University , Baton Rouge, Louisiana
| | - J Michael Salbaum
- Pennington Biomedical Research Center, Louisiana State University , Baton Rouge, Louisiana
| | - Jacqueline M Stephens
- Pennington Biomedical Research Center, Louisiana State University , Baton Rouge, Louisiana
- Department of Biological Sciences, Louisiana State University , Baton Rouge, Louisiana
| |
Collapse
|
8
|
Boudreau A, Fuller S, Ribnicky DM, Richard AJ, Stephens JM. Groundsel Bush (Baccharis halimifolia) Extract Promotes Adipocyte Differentiation In Vitro and Increases Adiponectin Expression in Mature Adipocytes. Biology (Basel) 2018; 7:biology7020022. [PMID: 29587377 PMCID: PMC6022969 DOI: 10.3390/biology7020022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/11/2018] [Revised: 03/23/2018] [Accepted: 03/23/2018] [Indexed: 12/11/2022]
Abstract
An ethanolic extract of Baccharis halimifolia (groundsel bush, GB), which is a native Louisiana plant with documented use in Creole folk medicine, has been shown to inhibit lipopolysaccharide (LPS)-induced inflammation in cultured macrophages. Here, we examine the effects of GB on adipocyte development and function, as these processes are attractive targets for intervention in insulin resistance. Oil Red O neutral lipid staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and immunoblotting were used to measure GB effects on lipid accumulation, gene expression, and protein abundance, respectively. In differentiating 3T3-L1 adipocytes, GB enhanced lipid accumulation and increased expression of several adipogenic genes (GLUT4, aP2, ADPN, CEBPα, FAS, and PPARγ). Protein levels of two of these adipogenic markers (aP2 and adiponectin) were examined and found to be induced by GB treatment. In mature adipocytes, GB reduced the gene expression of resistin, a pro-inflammatory endocrine factor, increased the adiponectin protein levels in a time-dependent manner, and substantially attenuated the TNF-alpha-induced reduction in adiponectin. In macrophages, GB reduced the expression of pro-inflammatory genes that were induced by LPS. GB produces metabolically favorable changes in differentiating adipocytes, mature adipocytes, and macrophages in vitro, suggesting its potential use as a dietary supplement or nutraceutical to support metabolic health and resiliency.
Collapse
Affiliation(s)
- Anik Boudreau
- Pennington Biomedical Research Center, Louisiana State University Baton Rouge, Baton Rouge, LA 70808, USA.
| | - Scott Fuller
- Pennington Biomedical Research Center, Louisiana State University Baton Rouge, Baton Rouge, LA 70808, USA.
| | - David M Ribnicky
- Biotech Center, Rutgers University, New Brunswick, NJ 08901, USA.
| | - Allison J Richard
- Pennington Biomedical Research Center, Louisiana State University Baton Rouge, Baton Rouge, LA 70808, USA.
| | - Jacqueline M Stephens
- Pennington Biomedical Research Center, Louisiana State University Baton Rouge, Baton Rouge, LA 70808, USA.
| |
Collapse
|
9
|
Berinstein N, Smyth L, Pennell N, Weerasinghe R, Cheung M, Imrie K, Spaner D, Chodirker L, Piliotis E, Milliken V, Boudreau A, Zhang L, Reis M, Chesney A, Good D, Ghorab Z, Buckstein R. PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- N. Berinstein
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - L. Smyth
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - N. Pennell
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - R. Weerasinghe
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - M. Cheung
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - K. Imrie
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - D. Spaner
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - L. Chodirker
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - E. Piliotis
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - V. Milliken
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - A. Boudreau
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - L. Zhang
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| | - M. Reis
- Laboratory Medicine; Sunnybrook Health Sciences Centre; Toronto Canada
| | - A. Chesney
- Laboratory Medicine; Sunnybrook Health Sciences Centre; Toronto Canada
| | - D. Good
- Pathology; Kingston General Hospital; Kingston Canada
| | - Z. Ghorab
- Laboratory Medicine; Sunnybrook Health Sciences Centre; Toronto Canada
| | - R. Buckstein
- Hematology Oncology; Odette Cancer Centre, Sunnybrook Health Sciences Centre; Toronto Canada
| |
Collapse
|
10
|
Sussman J, Varela N, Cheung M, Hicks L, Kraftcheck D, Mandel J, Fraser G, Jimenez-Juan L, Boudreau A, Sajkowski S, McQuillan R. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol 2016; 23:e499-e513. [PMID: 27803611 PMCID: PMC5081023 DOI: 10.3747/co.23.3265] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE This evidence summary set out to assess the available evidence about the follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment. METHODS The medline and embase databases and the Cochrane Database of Systematic Reviews were searched for evidence published between 2000 and August 2015 relating to lymphoma survivorship follow-up. The evidence summary was developed by a Working Group at the request of the Cancer Care Ontario Survivorship and Cancer Imaging programs because of the absence of evidence-based practice documents in Ontario for the follow-up and surveillance of asymptomatic patients with lymphoma in complete remission. RESULTS Eleven retrospective studies met the inclusion criteria. The proportion of relapses initially detected by clinical manifestations ranged from 13% to 78%; for relapses initially detected by imaging, the proportion ranged from 8% to 46%. Median time for relapse detection ranged from 8.6 to 19 months for patients initially suspected because of imaging and from 8.6 to 33 months for those initially suspected because of clinical manifestations. Only one study reported significantly earlier relapse detection for patients initially suspected because of clinical manifestations (mean: 4.5 months vs. 6.0 months, p = 0.042). No benefit in terms of overall survival was observed for patients depending on whether their relapse was initially detected because of clinical manifestations or surveillance imaging. SUMMARY Findings in the present study support the importance of improving awareness on the part of survivors and clinicians about the symptoms that might be associated with recurrence. The evidence does not support routine imaging for improving outcomes in this patient population.
Collapse
Affiliation(s)
- J. Sussman
- Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton
| | - N.P. Varela
- Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton
| | - M. Cheung
- Odette Cancer Centre, Sunny-brook Health Sciences Centre, Toronto
| | - L. Hicks
- Division of Hematology/Oncology, St. Michael’s Hospital, Toronto
| | - D. Kraftcheck
- Provincial Primary Care and Cancer Network, Hamilton Niagara Haldimand Brant, Grimsby
| | - J. Mandel
- Department of Diagnostic Imaging and Nuclear Medicine, Oakville Trafalgar Memorial Hospital, Oakville
| | - G. Fraser
- Division of Malignant Hematology, Juravinski Cancer Centre, Hamilton
| | | | - A. Boudreau
- Sunnybrook Health Sciences Centre, Toronto and
| | - S. Sajkowski
- Cancer Care Ontario Patient and Family Advisor, Toronto, ON
| | - R. McQuillan
- Cancer Care Ontario Patient and Family Advisor, Toronto, ON
| |
Collapse
|
11
|
Boudreau A, Cheng DM, Ruiz C, Ribnicky D, Allain L, Brassieur CR, Turnipseed DP, Cefalu WT, Floyd ZE. Screening native botanicals for bioactivity: an interdisciplinary approach. Nutrition 2014; 30:S11-6. [PMID: 24985099 DOI: 10.1016/j.nut.2014.02.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Revised: 02/25/2014] [Accepted: 02/25/2014] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Plant-based therapies have been used in medicine throughout recorded history. Information about the therapeutic properties of plants often can be found in local cultures as folk medicine is communicated from one generation to the next. The aim of this study was to identify native Louisiana plants from Creole folk medicine as a potential source of therapeutic compounds for the treatment of insulin resistance, type 2 diabetes, and related disorders. METHODS We used an interdisciplinary approach combining expertise in disciplines ranging from cultural anthropology and botany to biochemistry and endocrinology to screen native southwest Louisiana plants. Translation of accounts of Creole folk medicine yielded a list of plants with documented use in treating a variety of conditions, including inflammation. These plants were collected, vouchered, and catalogued before extraction of soluble components. Extracts were analyzed for bioactivity in regulating inflammatory responses in macrophages or fatty acid-induced insulin resistance in C2C12 skeletal muscle cells. RESULTS Several extracts altered gene expression of inflammatory markers in macrophages. Multiplex analysis of kinase activation in insulin-signaling pathways in skeletal muscle also identified a subset of extracts that alter insulin-stimulated protein kinase B phosphorylation in the presence of fatty-acid-induced insulin resistance. CONCLUSION An interdisciplinary approach to screening botanical sources of therapeutic agents can be successfully applied to identify native plants used in folk medicine as potential sources of therapeutic agents in treating insulin resistance in skeletal muscle or inflammatory processes associated with obesity-related insulin resistance.
Collapse
Affiliation(s)
- Anik Boudreau
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - Diana M Cheng
- Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA
| | - Carmen Ruiz
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | - David Ribnicky
- Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA
| | - Larry Allain
- USGS National Wetlands Research Center, Lafayette, Louisiana, USA
| | - C Ray Brassieur
- University of Louisiana at Lafayette, Lafayette, Louisiana, USA
| | | | - William T Cefalu
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | | |
Collapse
|
12
|
Boucher JG, Boudreau A, Atlas E. Bisphenol A induces differentiation of human preadipocytes in the absence of glucocorticoid and is inhibited by an estrogen-receptor antagonist. Nutr Diabetes 2014; 4:e102. [PMID: 24418828 PMCID: PMC3904083 DOI: 10.1038/nutd.2013.43] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Accepted: 12/08/2013] [Indexed: 11/30/2022] Open
Abstract
Background: Obesity is a major health concern in the developed world, and increasing evidence suggests that exposures to common environmental substances may enhance the risk for the development of this disease. Objectives: The current study examines the effect of the ubiquitous plastic monomer bisphenol A (BPA) on the differentiation of primary human preadipocytes in vitro and the role of the estrogen and glucocorticoid receptors. Methods: In this study, the mechanism of BPA-induced adipogenesis in preadipocytes from donors with healthy body mass index in the absence of exogenous glucocorticoid was evaluated. The effects of estradiol, the estrogen-receptor (ER) antagonist ICI and the glucocorticoid receptor (GR) antagonist RU486 on BPA-induced adipogenesis were examined. The expression levels of key adipogenic factors were assessed. Results: Treatment of preadipocytes with 1–50 μM BPA induced a dose-dependent increase in differentiation and lipid accumulation as determined by lipid staining and triacylglyceride quantification. BPA also induced expression of the adipogenic markers aP2, adipsin, peroxisome proliferator-activated receptor γ and the CCAAT-enhancer-binding proteins α and β. Co-treatment of cells with ICI inhibited the BPA-induced increase in aP2 levels, while treatment with ICI or estradiol alone had no effect. Treatment of cells with the GR antagonist RU486 had no effect on BPA-induced differentiation as evaluated by aP2 levels. Conclusions: This study is one of the first to show that BPA induces human adipocyte differentiation in the absence of exogenous glucocorticoid through a non-classical ER pathway rather than through GR activation. These studies add to the growing evidence that endocrine-disrupting chemicals such as BPA have the potential to modulate adipogenesis and impact human biology.
Collapse
Affiliation(s)
- J G Boucher
- In Vitro Molecular Toxicology Laboratory, Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada
| | - A Boudreau
- In Vitro Molecular Toxicology Laboratory, Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada
| | - E Atlas
- In Vitro Molecular Toxicology Laboratory, Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada
| |
Collapse
|
13
|
Coppé JP, Chen Z, Mori M, Boudreau A, van 't Veer L. Abstract P4-05-02: Phospho-reactome measurements reveal heterogenic kinase signatures. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treating cancer increasingly relies on targeting kinases, because their oncogenic activity drive tumorigenesis. Discovering which active mechanisms of disease progression can be efficiently targeted, and knowing whether kinase networks circumvent therapeutic interventions, are challenges researchers and clinicians face. Surprisingly however, measuring the phosphorylating activity of kinases, and potentially monitoring the functionality of the entire human phospho-reactome at once, remains largely unexplored. We developed a semi-high throughput assay to monitor the phospho-catalytic activity of kinase enzymes, using their biological targets as phospho-sensors. We successfully used this assay to identify oncogenic phospho-signatures prevalent in breast cancer, and can be used to establish drug-sensitivity profiles in models of kinase-targeted therapies.
Methods: We first defined how to computationally build a library of peptide sensors established from confirmed kinase substrates’ phosphorylation sites. Precisely, we used computational methods to create a unique phospho-repertoire cataloguing 3,408 peptide sequences established from validated human proteins’ phosphorylation sites, curated from 38 public databases. Second, we experimentally used these biologically relevant probes in multiplex assays to quantify the catalytic state of kinases. Specifically, a kinome-representative 242-peptide set was developed into an ATP-consumption screen to identify the activity signatures of EGFR, MAPK, AKT, ABL and SRC family kinases, and explore 642 kinase/substrate nodes. Next, we described analysis methods to derive phospho-signatures from semi-high throughput ATP-consumption measurements. We validated the assay using isogenic culture model of basal-like breast cancer (HMT-3522 S1 and T4-2), and cell lines harboring EGFR/HER2-oncogenic alterations such as MDA-MB-231, MCF7 or T47D.
Results: The differential phosphorylation activity of 25 recombinant, active kinase enzymes was successfully captured. In cancer cell extracts, hyper-activated EGFR, ERK, MEK, AKT, and SRC kinases originally identified by immuno-detection were reliably and specifically detectable using the peptide-based kinase-activity assay. The phospho-sensing assay revealed the heterogeneity of active kinase signaling circuits among different breast cancer cells.
Conclusion: This unique strategy and resources allow to comprehensively measure the catalytic activity of multitude kinases at once, representing a new molecular dimension to characterize biological samples. We will use such new phospho-reactome profiling system to determine the efficacy of new combinatorial therapies, and define how chemotherapeutic interventions lead to the reprogramming of phospho-circuits.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-05-02.
Collapse
Affiliation(s)
- J-P Coppé
- University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA
| | - Z Chen
- University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA
| | - M Mori
- University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA
| | - A Boudreau
- University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA
| | - L van 't Veer
- University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA
| |
Collapse
|
14
|
Hasek BE, Boudreau A, Shin J, Feng D, Hulver M, Van NT, Laque A, Stewart LK, Stone KP, Wanders D, Ghosh S, Pessin JE, Gettys TW. Remodeling the integration of lipid metabolism between liver and adipose tissue by dietary methionine restriction in rats. Diabetes 2013; 62:3362-72. [PMID: 23801581 PMCID: PMC3781441 DOI: 10.2337/db13-0501] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Dietary methionine restriction (MR) produces an integrated series of biochemical and physiological responses that improve biomarkers of metabolic health, limit fat accretion, and enhance insulin sensitivity. Using transcriptional profiling to guide tissue-specific evaluations of molecular responses to MR, we report that liver and adipose tissue are the primary targets of a transcriptional program that remodeled lipid metabolism in each tissue. The MR diet produced a coordinated downregulation of lipogenic genes in the liver, resulting in a corresponding reduction in the capacity of the liver to synthesize and export lipid. In contrast, the transcriptional response in white adipose tissue (WAT) involved a depot-specific induction of lipogenic and oxidative genes and a commensurate increase in capacity to synthesize and oxidize fatty acids. These responses were accompanied by a significant change in adipocyte morphology, with the MR diet reducing cell size and increasing mitochondrial density across all depots. The coordinated transcriptional remodeling of lipid metabolism between liver and WAT by dietary MR produced an overall reduction in circulating and tissue lipids and provides a potential mechanism for the increase in metabolic flexibility and enhanced insulin sensitivity produced by the diet.
Collapse
Affiliation(s)
- Barbara E. Hasek
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Anik Boudreau
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Jeho Shin
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Daorong Feng
- Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York
| | - Matthew Hulver
- Department of Human Nutrition, Foods, and Exercise, Virginia Tech, Blacksburg, Virginia
| | - Nancy T. Van
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Amanda Laque
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Laura K. Stewart
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Kirsten P. Stone
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Desiree Wanders
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Sujoy Ghosh
- Laboratory of Computational Biology, Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | - Jeffrey E. Pessin
- Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York
| | - Thomas W. Gettys
- Laboratories of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana
- Corresponding author: Thomas W. Gettys,
| |
Collapse
|
15
|
Boudreau A, Elias SG, Yau C, Wolf DM, van't Veer LJ. Abstract P4-09-02: A robust signature of long-term clinical outcome in breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Multigene prognostic signatures derived from high-dimensional mRNA expression data have been proposed to forecast patient outcome and predict chemotherapy benefit more accurately than standard clinical parameters. However, many prognostic signatures fail to predict late recurrences occurring 10 or more years following initial diagnosis. Furthermore, breast cancer subtypes canonically associated with favorable biology, particularly estrogen-receptor positive disease, are characterized by a higher frequency of late recurrences. Patients identified as being at a higher risk of late recurrence might benefit from more prolonged systemic (hormonal) therapy; as such, the goal of this research has been to develop a prognostic signature that can faithfully stratify patient risk up to and beyond 10 years of follow-up.
Methods: A novel multiplexed Cox modeling approach was applied to microarray data obtained from an untreated, node-negative patient cohort with long-term follow-up (n = 141) to train the signature. The long-term prognostic signature was subsequently validated in an additional group of patients (n = 154) that were mostly node-positive (94%) and administered adjuvant chemotherapy (71%). The performance of the signature was compared to existing clinicopathological parameters and genomic signatures using Cox proportional hazards analysis. Logistic regression modeling was employed to evaluate the added benefit to discriminatory accuracy obtained by incorporating the long-term prognostic signature alongside current biomarkers to predict 10-year overall survival.
Results: The long-term signature was able to stratify patient risk with unprecedented accuracy compared to standard clinicopathological and genomic features in both the training and the validation cohorts; none of the patients predicted to have good biology (n = 47 and 38) died within 10 years in either cohort, whereas only 34% and 44% of patients predicted to have poor biology (n = 47 and 46) survived 10 years in the training and validation cohorts, respectively. Within the validation series, the signature was able to identify patients at risk of metastasis with the highest hazard ratio in comparison to other prognostic signatures (univariate hazard ratio of 14.0 [95% CI 3.2–58; p = 0.00083], adjusted hazard ratio of 5.2 [95% CI 1.2–22; p = 0.0257] when corrected for standard clinicopathological markers). Adding the long-term prognostic signature to existing prognostic biomarkers led to significantly improved classification of patients into appropriate 10-year overall survival risk categories (Net Reclassification Improvement of 25.1% in validation series at >5% risk threshold, p = 0.0123).
Conclusions: We were able to identify a 200-gene long-term signature able to stratify patient risk with superior accuracy over a relatively long follow-up period. We are currently using this algorithm to develop prognostic signatures for other cancer types, and are using similar multiplexed algorithms to develop gene signatures able to predict response to neoadjuvant therapy.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-09-02.
Collapse
Affiliation(s)
- A Boudreau
- University of California, San Francisco; Netherlands Cancer Institute
| | - SG Elias
- University of California, San Francisco; Netherlands Cancer Institute
| | - C Yau
- University of California, San Francisco; Netherlands Cancer Institute
| | - DM Wolf
- University of California, San Francisco; Netherlands Cancer Institute
| | - LJ van't Veer
- University of California, San Francisco; Netherlands Cancer Institute
| |
Collapse
|
16
|
Wolf DM, Yau C, Magbanua M, Boudreau A, Davis S, Haqq C, Park J, Esserman L, van't Veer L. Abstract P2-05-01: Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prior gene expression profiling studies have identified markers that are predictive of chemotherapy response using pre-treatment biopsies. However, this approach does not account for chemotherapy-induced perturbation in signaling within tumors early in treatment that may predict response to therapy with superior sensitivity to baseline signatures. We hypothesized that measuring early changes in gene expression induced by neoadjuvant chemotherapy might yield improved markers of treatment efficacy and patient outcome.
Methods: Transcriptome data from 34K probe cDNA microarrays were assembled using serial biopsies obtained from 36 I-SPY 1 TRIAL patients before treatment (T1), and 24-72 hours after beginning neoadjuvant anthracycline-based chemotherapy (T2). Outcome parameters included residual cancer burden (RCB) after therapy and recurrence free survival (RFS). Gene expression changes occurring between T1 and T2 (T2-T1) were compared between known responders (RCB 0/1) and non-responders (RCB 2/3) using a permutation test based on the t-statistic; Cox proportional hazards modeling was used to identify early response genes associated with RFS. Due to the small sample sizes, we adopted a relaxed significance threshold for outcome associations (p-value<0.005 without multiple testing correction). Pathway analyses were performed with Ingenuity IPA software.
Results: 97 genes were found to be differentially altered upon comparing early gene expression changes (T2-T1) between responders (RCB 0/1) and non-responders (RCB 2/3). Ingenuity IPA software identified cell cycle as the top enriched pathway (p = 0.0008) among these differentially altered genes, with responders showing relative up-regulation of translation regulator EIF4EBP1 and cell cycle regulators CDKN2B and SMARCB1 after treatment. Survival analysis identified changes (T2-T1) in 293 genes as significantly associated with RFS; these genes were enriched in pathways including lipid antigen presentation by CD1, cell death and drug metabolism, and notch signaling. Surprisingly, only 4 genes were associated with both RCB and RFS, likely reflecting a prognostic signal from the many non-responding patients with favorable outcomes. Intrinsic subtype assignments were 75% concordant between time points T1 and T2, with basal classifications remaining stable (13/13) and some inter-conversion among LumA, LumB, Her2, and Normal (9/23). Interestingly, a larger number of genes were associated with chemotherapy response when one considered the change in expression (T2-T1), rather than absolute expression levels at T1 (17 genes) or at T2 (87 genes). Moreover, there was negligible overlap between these three response associated gene sets (T1, T2, and T2-T1 change), indicating that early expression changes may provide information beyond signatures obtained at static time points.
Conclusion: These analyses suggest that pre-treatment, early treatment and early changes provide non-redundant information on chemotherapy responsiveness and outcome. Early expression changes might be combined with data from pre-treatment biopsies to construct early predictors of non-response, an essential component within an adaptive treatment framework.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-01.
Collapse
Affiliation(s)
- DM Wolf
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - C Yau
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - M Magbanua
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - A Boudreau
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - S Davis
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - C Haqq
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - J Park
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - L Esserman
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - L van't Veer
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | | |
Collapse
|
17
|
Mori M, Chen Z, Boudreau A, van't VL, Coppé JP. Abstract P5-05-01: Catalogued phospho-sensing peptides identifying active, oncogenic kinase signatures. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Phospho-signaling networks represent one of the most clinically and therapeutically important frontiers of biology and medicine. Yet, measuring the phospho-catalytic activity of kinases, and monitoring the functionality of the entire kinome network at once remains largely unexplored. In particular, a highly convenient tool would be the advent of a microarray-like chip to comprehensively map phosphorylation networks to identify kinase signatures underlying cancer types and guide therapeutic interventions. In order to create such a kinase-sensing platform, we developed a library of peptide probes capable of reporting on the catalytic activity of kinases. The well-studied EGFR and SRC kinase network measurements serve as proof of concept.
Methods: We developed a human kinase protein and peptide repertoire from thousands of publications and >30 public databases computationally curated, filtered and merged, suitable to act as peptide beacons to evaluate enzymes' activity. Our database catalogues 916 kinase enzymes, 1913 substrate proteins, 6173 distinctive kinase-substrate active nodes, and compiles 2702 unique biological kinase peptide targets that all represent biologically relevant, latent nano-sensors usable to comprehensively track kinase signaling networks. Here, a representative set of 33 out of 417 peptides predicted to be specifically targeted by EGFR and SRC tyrosine kinase families and 17 control peptides, is tested for their potential kinase-activity reporting ability using a common luminescence ATP-consumption assay. We further validated the peptide screen in biological extracts using an isogenic culture model of basal like breast cancer (HMT-3522 S1 and T4-2).
Results: The differential phosphorylation activity of recombinant, active kinase enzymes (EGFR, ERBB2, SRC, HCK, FYN, FRK, LYN, LCK) was successfully detected by ATP-consumption measurement using the 50 peptides in time course experiments (0.25–4 hours) with evidence of selectively. Subsets of these data were confirmed by SRC kinase inhibitor treatments and dilution assays (0.1–5ng/ul kinase enzymes). Increased presence of activated SRC kinase in biological extracts from T4-2 breast cancer cells compared to nonmalignant S1 cells was shown by significantly elevated phosphorylation of 10 tested peptides (maximum elevation was shown with a SRC -specific reporting peptide and increased from 4 to 73% ATP consumption in S1 versus T4-2 cells, respectively).
Conclusion: These data demonstrate that the tested peptides can monitor kinases' activity. The peptide database can serve as a resource to provide sensitive and specific phospho-sensing probes, used to directly and specifically evaluate the activity of kinases, and can potentially support the identification of the entire, active, oncogenic kinome. Using this resource, we were able to identify peptides with evidence of specificity in in vitro and ex culture assays. Our efforts now concentrate on expanding this approach into a functional kinomic-screening platform in multiplex array format. Ultimately, we hope to translate such device into the clinic, and map phosphorylation signatures that cause breast malignancies and to guide tailor-made therapies.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-05-01.
Collapse
Affiliation(s)
- M Mori
- University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA
| | - Z Chen
- University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA
| | - A Boudreau
- University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA
| | - Veer L van't
- University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA
| | - J-P Coppé
- University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA
| |
Collapse
|
18
|
Wang ZQ, Yu Y, Zhang XH, Floyd ZE, Boudreau A, Lian K, Cefalu WT. Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice. Int J Nanomedicine 2012; 7:2999-3012. [PMID: 22787396 PMCID: PMC3390996 DOI: 10.2147/ijn.s30887] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
AIM To compare the effects of dietary fibers on hepatic cellular signaling in mice. METHODS Mice were randomly divided into four groups (n = 9/group): high-fat diet (HFD) control, cellulose, psyllium, and sugarcane fiber (SCF) groups. All mice were fed a HFD with or without 10% dietary fiber (w/w) for 12 weeks. Body weight, food intake, fasting glucose, and fasting insulin levels were measured. At the end of the study, hepatic fibroblast growth factor (FGF) 21, AMP-activated protein kinase (AMPK) and insulin signaling protein content were determined. RESULTS Hepatic FGF21 content was significantly lowered, but βKlotho, fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, and peroxisome proliferator-activated receptor alpha proteins were significantly increased in the SCF group compared with those in the HFD group (P < 0.01). SCF supplementation also significantly enhanced insulin and AMPK signaling, as well as decreased hepatic triglyceride and cholesterol in comparison with the HFD mice. The study has shown that dietary fiber, especially SCF, significantly attenuates lipid accumulation in the liver by enhancing hepatic FGF21, insulin, and AMPK signaling in mice fed a HFD. CONCLUSION This study suggests that the modulation of gastrointestinal factors by dietary fibers may play a key role in both enhancing hepatic multiple cellular signaling and reducing lipid accumulation.
Collapse
Affiliation(s)
- Zhong Q Wang
- Nutrition and Diabetes Research Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
| | | | | | | | | | | | | |
Collapse
|
19
|
Wolf DM, Yau C, Benz S, Vaske C, Stuart J, Roy R, Olshen A, Boudreau A, Haussler D, Gray J, Spellman P, Davis S, Hylton N, Van Veer L, Esserman L. P1-06-09: Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-06-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A major challenge in interpreting high-throughput multianalyte genomic data sets such as those produced by the ISPY clinical trials is data integration and interpretation within the context of biologically relevant pathways. To address this need, the data analysis tool PARADIGM (PAthway Recognition Algorithm using Data Integration on Genomic Models) was developed to infer the activities of genetic pathways by integrating any number of functional genomic data sets for a given patient sample into a pathway activity profile.
Methods: We used PARADIGM to integrate gene expression (Agilent 44K) and DNA copy number data (AFFY 22K and 330K MIP) from 133 ISPY-1 patients into pathway component activity levels for approximately 1400 curated signal transduction, transcriptional and metabolic pathways superimposed onto a single non-redundant ‘SuperPathway'. These pathway activities then become the substrate for statistical analyses to identify pathways characterizing different breast cancer subtypes, as well as those associated with recurrence and response to neoadjuvant chemotherapy within breast cancer subgroups. To identify subtype-specific pathway activities, we used ANOVA for initial feature filtering followed by Tukey analysis with Benjamini Hochberg multiple testing correction. For other binary outcome comparisons we used Mann-Whitney (2-sample Wilcoxon) analysis. PARADIGM results were corroborated with pathway enrichment analysis and filtered for significance.
Results: In agreement with breast cancer cell line and other prior studies, basal-like and triple negative cancers are dominated by upregulation of the FOXM1 and MYC/Max subnetworks and downregulation of the FOXA1/ER signal transduction pathway, the converse of the activity pattern seen in luminal breast cancers. These and other subtype associations pass stringent multiple testing corrected significance tests. Though an association study of recurrence over the entire patient cohort mostly yields pathways characteristic of basal-like tumors, alternative pathway associations emerge when subtypes are analyzed individually for outcome and significance tests are relaxed to include features that pass un-corrected Wilcoxon significance tests and also generate highly significant pathway enrichment scores. Subtype-specific drivers of recurrence and chemo-resistance supported by this level of evidence include ALK1/2 (TGFB-BMP) and p53 effector signaling for basals and Syndecan-1 and c-MYC for luminals. Chemo-sensitivity pathways, assessed by association with pCR and RCB1, appear to be subtype-specific as well, with HDAC class 1 signaling, LRP6-Wnt, and IRE1alpha chaperones dominating basal-like cancers and c-MYB activity dominating Her2+ cancers, whereas chemo-sensitivity of HR+Her2- cancers though rare appears to be driven by the DNA damage axis (BRCA/BARD1). Conclusion: These and other similar analyses suggest that patients with TN or basal-like disease might benefit from the addition of ALK1 pathway inhibitors to treatment, whereas high risk HR+ patients might benefit from Syndecan-1 inhibitors. C-MYC/MAX inhibitors might benefit all high risk patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-09.
Collapse
Affiliation(s)
- DM Wolf
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - C Yau
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - S Benz
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - C Vaske
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - J Stuart
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - R Roy
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - A Olshen
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - A Boudreau
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - D Haussler
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - J Gray
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - P Spellman
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - S Davis
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - N Hylton
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - L Van Veer
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - L Esserman
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| |
Collapse
|
20
|
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills GB, Gray JW, Wolf DM, van ‘t Veer LJ. P5-01-05: Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Mutations in the catalytic domain of phosphatidylinositol 3-kinase (PIK3CA) are among the most frequently observed activating mutations in breast cancer. We used the I SPY 1 TRIAL, a group of biologically and clinically high risk patients molecularly profiled and treated with neoadjuvant chemotherapy, to determine the frequency of mutations and their relationship to pathologic complete response (pCR) and outcomes, within the entire cohort and within subtypes defined by growth and hormone receptor (HR) expression.
Methods: Patients enrolled in the I-SPY 1 TRIAL had a tumor size ≥3.0cm and were administered a doxorubicin-containing regimen, followed by a taxane, prior to surgery. Sequenom single nucleotide polymorphism (SNP) profiling was performed on breast tumor genomic DNA isolated from a subset of patients (n=152). A total of 149 SNPs covering 16 genes (including PIK3CA and AKT1/2/3) were analyzed. Mutations were tested for association with estrogen receptor (ER), progesterone receptor (PgR), and HER2 status, as well as pCR, using Fisher's exact test; associations between mutations and recurrence-free survival (RFS) were measured by log-rank tests. pCR was defined as no invasive tumor present in either the breast or axillary lymph nodes following neoadjuvant treatment.
Results: Of 149 mutations profiled in the cohort, 13 of the SNPs were observed. PIK3CA mutations were the most frequently observed in the panel (15.1%), followed by AKT1(E17K; 2.7%), CTNNB1 (D32; 1.4%), NRAS(Q61; 0.7%), and FGFR2(N549; 0.7%). Mutations in PIK3CA or AKT1 was associated with ER-positivity (p=0.0047) and PgR-positivity (p=0.044). Within receptor subtypes, the frequencies of PIK3CA/AKT1 mutations were also significantly different (HR+HER2−: 27%:(18/68); HER2+ 20% (8/40) [HR+HER2+: 26%, HR-HER2+: 14%]; HR-HER2−: 0% (0/36), p<0.0008). Unlike previous reports (Loi et al, PNAS 2010), no significant association between PIK3CA/AKT mutation status and RFS was observed when we restricted our analysis to the adjuvant endocrine treated subset of the HR+HER2− patients (n=49; log rank p = 0.369). In contrast, and similar to cell line reports (Junttila et al, Cancer Cell 2009), PIK3CA mutations appears to associate with worse RFS within the small subset of trastuzumab treated HER2+ patients (n=22, 13 HR-HER2+, 9 HR+HER2−; log rank p=0.001), suggesting mutations may influence response. Similar analyses of a larger cohort are planned to confirm these observations.
Conclusions: Within the I-SPY 1 TRIAL cohort, PIK3CA and AKT1 mutations are much more frequent in the HR+ and HER2 subsets but are not predictive of response to therapy or outcome except potentially within the HER2+ subset. The potential link observed between activating PIK3CA/AKT mutations and trastuzumab resistance merits further investigation, as it may provide a clinical rationale for testing PIK3CA mutation status in HER2+ patients and investigating combinational therapies targeting this pathway, particularly in the HER2+HR+ subset which have an elevated risk for recurrence despite pCR and trastuzumab therapy.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-01-05.
Collapse
Affiliation(s)
- A Boudreau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - C Yau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - L Petrillo
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - K Stemke-Hale
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - GB Mills
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - JW Gray
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - DM Wolf
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - LJ van ‘t Veer
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| |
Collapse
|
21
|
Gettys T, Plaisance E, Boudreau A. Mechanisms and implications of the tissue-specific remodeling of lipid metabolism by dietary methionine restriction. Chem Phys Lipids 2011. [DOI: 10.1016/j.chemphyslip.2011.05.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Plaisance EP, Greenway FL, Boudreau A, Hill KL, Johnson WD, Krajcik RA, Perrone CE, Orentreich N, Cefalu WT, Gettys TW. Dietary methionine restriction increases fat oxidation in obese adults with metabolic syndrome. J Clin Endocrinol Metab 2011; 96:E836-40. [PMID: 21346062 PMCID: PMC3085194 DOI: 10.1210/jc.2010-2493] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE In preclinical reports, restriction of dietary methionine intake was shown to enhance metabolic flexibility, improve lipid profiles, and reduce fat deposition. The present report is the outcome of a "proof of concept" study to evaluate the efficacy of dietary methionine restriction (MR) in humans with metabolic syndrome. METHODS Twenty-six obese subjects (six male and 20 female) meeting criteria for metabolic syndrome were randomized to a diet restricted to 2 mg methionine/kg body weight per day and were provided capsules containing either placebo (n = 12) or 33 mg methionine/kg body weight per day (n = 14). Energy expenditure, body composition, insulin sensitivity, and biomarkers of metabolic syndrome were measured before and after 16 wk on the respective diets. RESULTS Insulin sensitivity and biomarkers of metabolic syndrome improved comparably in both dietary groups. Rates of energy expenditure were unaffected by the diets, but dietary MR produced a significant increase in fat oxidation (MR, 12.1 ± 6.0% increase; control, 8.1 ± 3.3% decrease) and reduction in intrahepatic lipid content (MR liver/spleen attenuation ratio, 8.1 ± 3.3% increase; control ratio, 2.2 ± 2.1% increase) that was independent of the comparable reduction in weight and adiposity that occurred in both groups. CONCLUSIONS Sixteen weeks of dietary MR in subjects with metabolic syndrome produced a shift in fuel oxidation that was independent of the weight loss, decreased adiposity, and improved insulin sensitivity that was common to both diets.
Collapse
Affiliation(s)
- Eric P Plaisance
- Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Plaisance EP, Henagan TM, Echlin H, Boudreau A, Hill KL, Lenard NR, Hasek BE, Orentreich N, Gettys TW. Role of beta-adrenergic receptors in the hyperphagic and hypermetabolic responses to dietary methionine restriction. Am J Physiol Regul Integr Comp Physiol 2010; 299:R740-50. [PMID: 20554934 DOI: 10.1152/ajpregu.00838.2009] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Dietary methionine restriction (MR) limits fat deposition and decreases plasma leptin, while increasing food consumption, total energy expenditure (EE), plasma adiponectin, and expression of uncoupling protein 1 (UCP1) in brown and white adipose tissue (BAT and WAT). beta-adrenergic receptors (beta-AR) serve as conduits for sympathetic input to adipose tissue, but their role in mediating the effects of MR on energy homeostasis is unclear. Energy intake, weight, and adiposity were modestly higher in beta(3)-AR(-/-) mice on the Control diet compared with wild-type (WT) mice, but the hyperphagic response to the MR diet and the reduction in fat deposition did not differ between the genotypes. The absence of beta(3)-ARs also did not diminish the ability of MR to increase total EE and plasma adiponectin or decrease leptin mRNA, but it did block the MR-dependent increase in UCP1 mRNA in BAT but not WAT. In a further study, propranolol was used to antagonize remaining beta-adrenergic input (beta(1)- and beta(2)-ARs) in beta(3)-AR(-/-) mice, and this treatment blocked >50% of the MR-induced increase in total EE and UCP1 induction in both BAT and WAT. We conclude that signaling through beta-adrenergic receptors is a component of the mechanism used by dietary MR to increase EE, and that beta(1)- and beta(2)-ARs are able to substitute for beta(3)-ARs in mediating the effect of dietary MR on EE. These findings are consistent with the involvement of both UCP1-dependent and -independent mechanisms in the physiological responses affecting energy balance that are produced by dietary MR.
Collapse
Affiliation(s)
- Eric P Plaisance
- Laboratory of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Hasek BE, Stewart LK, Henagan TM, Boudreau A, Lenard NR, Black C, Shin J, Huypens P, Malloy VL, Plaisance EP, Krajcik RA, Orentreich N, Gettys TW. Dietary methionine restriction enhances metabolic flexibility and increases uncoupled respiration in both fed and fasted states. Am J Physiol Regul Integr Comp Physiol 2010; 299:R728-39. [PMID: 20538896 DOI: 10.1152/ajpregu.00837.2009] [Citation(s) in RCA: 162] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Dietary methionine restriction (MR) is a mimetic of chronic dietary restriction (DR) in the sense that MR increases rodent longevity, but without food restriction. We report here that MR also persistently increases total energy expenditure (EE) and limits fat deposition despite increasing weight-specific food consumption. In Fischer 344 (F344) rats consuming control or MR diets for 3, 9, and 20 mo, mean EE was 1.5-fold higher in MR vs. control rats, primarily due to higher EE during the night at all ages. The day-to-night transition produced a twofold higher heat increment of feeding (3.0 degrees C vs. 1.5 degrees C) in MR vs. controls and an exaggerated increase in respiratory quotient (RQ) to values greater than 1, indicative of the interconversion of glucose to lipid by de novo lipogenesis. The simultaneous inhibition of glucose utilization and shift to fat oxidation during the day was also more complete in MR (RQ approximately 0.75) vs. controls (RQ approximately 0.85). Dietary MR produced a rapid and persistent increase in uncoupling protein 1 expression in brown (BAT) and white adipose tissue (WAT) in conjunction with decreased leptin and increased adiponectin levels in serum, suggesting that remodeling of the metabolic and endocrine function of adipose tissue may have an important role in the overall increase in EE. We conclude that the hyperphagic response to dietary MR is matched to a coordinated increase in uncoupled respiration, suggesting the engagement of a nutrient-sensing mechanism, which compensates for limited methionine through integrated effects on energy homeostasis.
Collapse
Affiliation(s)
- Barbara E Hasek
- Laboratory of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Zhang Y, Huypens P, Adamson AW, Chang JS, Henagan TM, Boudreau A, Lenard NR, Burk D, Klein J, Perwitz N, Shin J, Fasshauer M, Kralli A, Gettys TW. Alternative mRNA splicing produces a novel biologically active short isoform of PGC-1alpha. J Biol Chem 2009; 284:32813-26. [PMID: 19773550 DOI: 10.1074/jbc.m109.037556] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
The transcriptional co-activator PGC-1alpha regulates functional plasticity in adipose tissue by linking sympathetic input to the transcriptional program of adaptive thermogenesis. We report here a novel truncated form of PGC-1alpha (NT-PGC-1alpha) produced by alternative 3' splicing that introduces an in-frame stop codon into PGC-1alpha mRNA. The expressed protein includes the first 267 amino acids of PGC-1alpha and 3 additional amino acids from the splicing insert. NT-PGC-1alpha contains the transactivation and nuclear receptor interaction domains but is missing key domains involved in nuclear localization, interaction with other transcription factors, and protein degradation. Expression and subcellular localization of NT-PGC-1alpha are dynamically regulated in the context of physiological signals that regulate full-length PGC-1alpha, but the truncated domain structure conveys unique properties with respect to protein-protein interactions, protein stability, and recruitment to target gene promoters. Therefore, NT-PGC-1alpha is a co-expressed, previously unrecognized form of PGC-1alpha with functions that are both unique from and complementary to PGC-1alpha.
Collapse
Affiliation(s)
- Yubin Zhang
- Laboratory of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Rankinen T, Boudreau A, Rice T, Leon AS, Rao D, Skinner JS, Bouchard C. A Quantitative Trait Locus For Maximal Exercise Heart Rate On Chromosome 10p13. Med Sci Sports Exerc 2005. [DOI: 10.1249/00005768-200505001-00868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
27
|
Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein NL. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15:283-90. [PMID: 14760123 DOI: 10.1093/annonc/mdh069] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The outcome of 20 patients with newly diagnosed mantle-cell lymphoma (MCL) treated on a prospective trial of autologous stem-cell transplantation (ASCT) and rituximab immunotherapy was compared with the outcome of 40 matched historical control patients treated with standard combination chemotherapy. PATIENTS AND METHODS Control patients with MCL were identified from a lymphoma database, and pairs were matched with patients receiving ASCT-rituximab for stage of disease, gender and age (+/-5 years). Only patients treated with an anthracycline- or cyclophosphamide-fludarabine-based regimen were included. RESULTS Seventeen of 20 patients who received ASCT-rituximab remain alive in remission at a median of 30 months from diagnosis; one patient relapsed 2 years post-ASCT, and two died at 7 and 11 months post-ASCT without evidence of lymphoma. Of 40 patients treated with conventional chemotherapy, with a median follow-up of 80 months, 33 have relapsed or progressed and 29 have died. Overall (OS) and progression-free (PFS) survival were superior in patients treated with ASCT-rituximab compared with those treated with conventional chemotherapy (PFS at 3 years, 89% versus 29%, P <0.00001; OS at 3 years, 88% versus 65%, P = 0.052). CONCLUSIONS This matched-pair analysis suggests that patients with advanced-stage MCL treated with ASCT-rituximab had statistically significantly better PFS and a trend toward better OS than patients treated with conventional chemotherapy. Longer follow-up will determine response duration and the true impact of this treatment strategy on PFS and OS.
Collapse
Affiliation(s)
- J Mangel
- Advanced Therapeutics Program, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Rankinen T, Rice T, Boudreau A, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Titin is a candidate gene for stroke volume response to endurance training: the HERITAGE Family Study. Physiol Genomics 2003; 15:27-33. [PMID: 12865504 DOI: 10.1152/physiolgenomics.00147.2002] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
A genome-wide linkage scan for endurance training-induced changes in submaximal exercise stroke volume (DeltaSV50) in the HERITAGE Family Study revealed two chromosomal regions (2q31-q32 and 10p11.2) with at least suggestive evidence of linkage among white families. Here we report a further characterization of the quantitative trait locus (QTL) in chromosome 2q31 and provide evidence that titin (TTN) is likely a candidate gene involved. The original linkage was detected with two markers (D2S335 and D2S1391), and the QTL covered approximately 25 million base pairs (Mb). We added 12 microsatellite markers resulting in an average marker density of one marker per 2.3 Mb. The evidence of linkage increased from P = 0.006 to P = 0.0002 and 0.00002 in the multi- and single-point analyses, respectively. The strongest evidence of linkage was seen with two markers in and near the TTN gene. Transmission/disequilibrium test (TDT) with the same marker set provided evidence for association with one of the TTN markers (D2S385; P = 0.004). TTN is a major contributor to the elasticity of cardiomyocytes and a key regulator of the Frank-Starling mechanism. Since TTN is the largest gene in the human genome, the challenge is to identify the DNA sequence variants contributing to the interindividual differences in cardiac adaptation to endurance training.
Collapse
Affiliation(s)
- Tuomo Rankinen
- Pennington Biomedical Research Center, Human Genomics Laboratory, Baton Rouge, Louisiana 70808-4124, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003; 14:758-65. [PMID: 12702531 DOI: 10.1093/annonc/mdg201] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Little is known about the pharmacokinetics of rituximab in an autologous stem cell transplant (ASCT) setting. PATIENTS AND METHODS We evaluated serum rituximab levels in 26 patients with follicular or mantle cell lymphoma treated with a combination of ASCT and immunotherapy. Patients received nine infusions of rituximab (375 mg/m(2)): one dose as an 'in vivo purge' prior to stem cell collection, and two 4-week cycles at 8 and 24 weeks following ASCT. Pre- and post-infusion serum rituximab levels were measured during the purging dose, with doses 1 and 4 of both sets of maintenance rituximab cycles, and 12 weeks and 24 weeks following treatment. RESULTS Rituximab levels were detectable after the first infusion, and peaked at a mean concentration of 463.8 micro g/ml after the final dose. Levels remained detectable 24 weeks after completion of treatment. There was a trend toward higher rituximab levels in patients with follicular lymphoma. Serum concentrations achieved during the maintenance cycles were similar to levels observed in patients with measurable lymphoma treated during 'the pivotal trial'. No correlation was observed between serum rituximab levels achieved in the minimal disease state and the risk of later clinical relapse, nor with the ability to achieve a molecular remission following ASCT. CONCLUSIONS The finding that patients treated in minimal disease states and at the time of active disease both achieve similar final serum rituximab concentrations after four infusions suggests that the pharmacokinetics are complex, and may not necessarily correlate with disease burden. The precise factors influencing rituximab clearance in patients with lymphoma are unresolved, and this remains an area of active research.
Collapse
MESH Headings
- Antibodies, Monoclonal/blood
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Bone Marrow Purging/methods
- Bone Marrow Purging/statistics & numerical data
- Humans
- Immunotherapy/methods
- Immunotherapy/statistics & numerical data
- Lymphoma, Follicular/blood
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/therapy
- Lymphoma, Mantle-Cell/blood
- Lymphoma, Mantle-Cell/immunology
- Lymphoma, Mantle-Cell/therapy
- Prospective Studies
- Rituximab
- Stem Cell Transplantation/methods
- Stem Cell Transplantation/statistics & numerical data
- Transplantation, Autologous
Collapse
Affiliation(s)
- J Mangel
- The Advanced Therapeutics Program, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Jacques H, Gascon A, Arul J, Boudreau A, Lavigne C, Bergeron J. Modified milk fat reduces plasma triacylglycerol concentrations in normolipidemic men compared with regular milk fat and nonhydrogenated margarine. Am J Clin Nutr 1999; 70:983-91. [PMID: 10584042 DOI: 10.1093/ajcn/70.6.983] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND A modified milk fat with reduced cholesterol was developed by fractionation technology. OBJECTIVE The effect of this modified milk fat on the lipoprotein profile of 21 normolipidemic men was compared with that of regular milk fat and nonhydrogenated margarine. DESIGN A crossover design was used for the administration of the 3 experimental diets, which provided 13240 kJ as 16% protein, 51% carbohydrates, 33-34% lipids, and 21 g fiber/d. The ratio of polyunsaturated to saturated fat was 1.3:1 for the margarine diet and 0.3:1 for the milk-fat diets. The cholesterol content of the modified milk-fat and margarine diets was similar (248 and 254 mg/d, respectively), but was significantly higher (428 mg/d) for the regular milk-fat diet. RESULTS Modified and regular milk fats did not change plasma total and LDL cholesterol significantly, but margarine did (P < 0.01). Furthermore, modified milk fat maintained initial HDL(2)-cholesterol concentrations, but margarine reduced this variable significantly (P < 0.05). These results can be explained by the lower ratio of polyunsaturated to saturated fat in the modified and regular milk-fat diets than in the margarine diet. Men who ingested modified milk fat had significantly (P < 0.05) lower total and VLDL-triacylglycerol and VLDL-cholesterol concentrations than did those who ingested either regular milk fat or margarine. This may have been, in part, because of the lower intestinal fat absorption with modified milk fat than with regular milk fat and margarine arising from changes in the melting properties of milk fat with fractionation. CONCLUSION A reduction in plasma triacylglycerol concentrations after the consumption of modified milk fat may prevent the onset of hypertriacylglycerolemia.
Collapse
Affiliation(s)
- H Jacques
- Département des Sciences des Aliments et de Nutrition, Faculté des Sciences de l'Agriculture et de l'Alimentation, Université Laval, Canada.
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
Bovine milk fat was fractionated using preparative reversed-phase high-performance liquid chromatography. The conditions consisted of two successive linear gradients of acetonitrile and tert-butylmethylether, followed by a final isocratic mixture of the two eluants, leading to triacylglycerols grouped by their partition number (PN). Fractions corresponding to partition numbers 32 to 50 were isolated and analyzed for fatty acid distribution between sn-1,3 and sn-2 positions by Grignard degradation. Results showed that the fatty acid distribution in milk fat triacylglycerols is nonrandom. The distribution of short-chain fatty acids, stearic (predominantly at sn-1,3 position) and palmitic (predominantly sn-2 position), did not change with triacylglycerol size. Medium-chain fatty acids were predominantly located at sn-2 position, but their proportion at this position decreased with triacylglycerol size. Oleic acid distribution was also size-dependent in that it was located in high proportions at sn-2 position in smaller triacylglycerols and vice versa. Results also showed that the sn-2 position was more unsaturated than sn-1,3 position in the PN range from 32 to 40, but it was more saturated in triacylglycerols with higher PN.
Collapse
Affiliation(s)
- P Angers
- Dairy Research Center (STELA), and Department of Food Science and Nutrition, Université Laval, Sainte-Foy, Québec, Canada
| | | | | | | |
Collapse
|
32
|
Gascon A, Arul J, Boudreau A, Lavigne C, Bergeron J, Jacques H. 4.P.159 Modified milk fat reduces triglyceride concentrations in healthy men compared to regular milk fat and non-hydrogenated margarine. Atherosclerosis 1997. [DOI: 10.1016/s0021-9150(97)89686-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
33
|
Abstract
Many patients in acute care hospitals experience constipation, yet the literature on constipation focuses on long-term care and does not provide tools for describing and analyzing bowel management from the perspective of health care professionals or patients. The article describes the development of a bowel management task force at one acute care hospital and the initial steps taken to improve clinical quality in this area. A multifaceted approach was used to collect baseline data on practice, expectations, and problems related to bowel management. Valuable data were obtained from both patients and health care providers that have provided direction for improving clinical outcomes and patient satisfaction.
Collapse
Affiliation(s)
- T Moore
- Department of Gerontology, Humber Memorial Hospital, Weston, Ontario, Canada
| | | | | |
Collapse
|
34
|
|
35
|
Lautier D, Poirier D, Boudreau A, Alaoui Jamali MA, Castonguay A, Poirier G. Stimulation of poly(ADP-ribose) synthesis by free radicals in C3H10T1/2 cells: relationship with NAD metabolism and DNA breakage. Biochem Cell Biol 1990; 68:602-8. [PMID: 2165410 DOI: 10.1139/o90-085] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
We have studied the effect of H2O2 and O2- produced by xanthine and xanthine oxidase on NAD catabolism, poly(ADP-ribose) synthesis, and production of DNA single-strand breaks in C3H10T1/2 cells. The results show a correlation between the induction of DNA single-strand breaks, the decrease of NAD pool, and the accumulation of polymer. New techniques, based on affinity chromatography and reversed-phase high pressure liquid chromatography, have allowed an accurate determination of polymer contents and showed a 20-fold stimulation of polymer biosynthesis induced by active oxygen species. Inhibition experiments performed with 3-aminobenzamide have shown that the decrease in NAD levels after exposure of cells to active oxygen species was caused by stimulation of poly(ADP-ribosyl)ation and of another cellular process.
Collapse
Affiliation(s)
- D Lautier
- Laboratoire du métabolisme du poly(ADP-ribose), Centre hospitalier de l'Université Laval, Ste-Foy, Qué., Canada
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Milk fat was fractionated into liquid (m.p. congruent to 12 degrees C), intermediate (m.p. congruent to 21 degrees C) and solid (m.p. congruent to 39 degrees C) fractions by three different processes--melt crystallization, short-path distillation and supercritical CO2 extraction--and the cholesterol content of these fractions determined. Cholesterol was enriched in the liquid fractions from all three processes, in particular about 80% of the cholesterol being found in the liquid fraction obtained by short-path distillation. The basis of migration of cholesterol into various milk fat fractions was explained by its affinity to various triglycerides (melt crystallization) and by vapour pressure and molecular weight (short-path distillation). It was more complex in the supercritical CO2 extraction process; the interplay of cholesterol affinity toward CO2 and its molar volume, and its vapour pressure enhancement under applied pressure play a role.
Collapse
Affiliation(s)
- J Arul
- Département de Sciences et Technologie des Aliments, Université Laval, Quebec, Canada
| | | | | | | | | |
Collapse
|
37
|
Makhlouf J, Arul J, Boudreau A, Verret P, Sahasrabudhe M. Fractionnement de la matière grasse laitière par cristallisation simple et son utilisation dans la fabrication de beurres mous. ACTA ACUST UNITED AC 1987. [DOI: 10.1016/s0315-5463(87)71194-8] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Boudreau A, Turcotte J. Analysis of Gamma Radionuclides in Selected Farm Produce of Oka, Quebec - A Niobium Mining Community. J Food Prot 1982; 45:905-908. [PMID: 30866259 DOI: 10.4315/0362-028x-45.10.905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
An investigation of the gamma emitting radionuclides present in selected farm produce of Oka, Quebec, was conducted. In the three categories of foodstuffs, such as cheese, apple and maple sugar, obtained from the immediate vicinity of niobium mill tailings piles, distinguishable radioactivity from natural sources and worldwide fallout was evident. Except for lead-214 and radium-226, the tailings spectrum showed a typical pattern of natural background value. With the exception of lead-212, uranium-235, thallium-208 and actinium- 228, all radionuclides in farm produce were near or below levels of detection. There was no significant difference in the radiation level of food samples grown in control areas.
Collapse
Affiliation(s)
- A Boudreau
- Département de sciences et technologie des aliments, Faculté des sciences de l'agriculture et de l'alimentation; Centre de recherche en nutrition, Pavillon Comtois; and Département de chimie, Faculté des sciences et de génie, Université Laval, Sainte-Foy, Québec, Canada GIK 7P4
| | - J Turcotte
- Département de sciences et technologie des aliments, Faculté des sciences de l'agriculture et de l'alimentation; Centre de recherche en nutrition, Pavillon Comtois; and Département de chimie, Faculté des sciences et de génie, Université Laval, Sainte-Foy, Québec, Canada GIK 7P4
| |
Collapse
|
39
|
Boudreau A. [Hospital responsibility in the treatment of drug addiction]. Vie Med Can Fr 1972; 1:872-7. [PMID: 4654985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
40
|
|
41
|
|
42
|
Abstract
Hydrolysis of tricaprylin by pancreatic lipase resulted in a stepwise hydrolysis, triglyceride to diglyceride to monoglyceride, as has been obtained with long-chain triglycerides. However, hydrolysis rates were much faster and considerable amounts of free glycerol were formed. Hydrolysis of an equimolar mixture of tricaprylin and triolein indicated that some of the short-chain fatty acid was released from the 2-position before all of the oleic acid was released from the 1-position. Hydrolysis of genuine and randomized milk fat resulted in preferential hydrolysis of glycerides containing short-chain fatty acids. This phenomenon was not dependent on a specific distribution of these acids, since it also occurred with the randomized fat. It was concluded that part of the short-chain fatty acids of milk fat is located in the 2-position. The distribution of caprylic and capric acids between the 1- and 2-positions is approximately at random. Lauric, myristic, and palmitic acids are predominantly located in the 2-position, and stearic and oleic acids in the 1-position, of milk fat glycerides.
Collapse
|